| Name | Title | Contact Details |
|---|
Hawkins is a formulator, manufacturer, blender, distributor, and sales agent for thousands of industrial chemicals and reagent grade laboratory chemicals sold to municipalities and businesses throughout the Central United States. Thousands of water treatment facilities, manufacturers, food and dairy producers, research labs and many other organizations depend on Hawkins for the chemical products they need. These products range from potassium carbonate to chlorine to FCC grade citrates and phosphates. Our Mission To exceed our customers expectations as a high-quality, service-oriented chemical supplier. We will adapt quickly to the changing chemical needs of customers with a keen focus on technical expertise, teamwork, safety, profitability, and responsible care of the environment and of our community.
Suffolk Credit Union is a financial cooperative located on Long Island, New York, with over 55 years of service to the community. Established in 1967, it operates on a non-profit basis, owned and controlled by its members. The credit union offers a variety of financial services, including checking and savings accounts, personal and auto loans, mortgages, credit cards, and investment services. In addition to traditional banking, Suffolk Credit Union provides financial planning assistance, retirement planning, and insurance services. Members can access their accounts conveniently through online and mobile banking. The credit union is dedicated to community involvement, partnering with local organizations and educational institutions to support development initiatives. With ten branch locations across Long Island, Suffolk Credit Union serves individuals and families in Suffolk and Nassau Counties, focusing on personalized service and financial literacy.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Alliance Animal Health is a multi-site business partner to veterinarians across the US. Alliance Animal Health allows veterinarians to continue to practice medicine independently while providing resources and assistance in business operations. Veterinarians retain all the benefits of being an independent practice, but gain the additional advantages associated with becoming part of a larger organization. These include access to professional marketing, inventory management expertise, purchasing power, recruiting support, collaborative synergies, and financial resources. Our network of general practice and emergency hospitals is as individual as you, and we like it that way! Our network of highly skilled partners and associate veterinarians work hard to deliver the quality of personalized care and attention that our profession deserves. We pride ourselves on maintaining a culture of open communication and collaboration to remain innovative and cutting edge in todays veterinary environment without disrupting the medical autonomy of our qualified veterinarians.